Reductions in insulin sensitivity and insulin secretion are the hallmarks of T2DM, and a large number of studies have revealed that hyperglycemia and hyperlipidemia are critical risk factors for islet β-cell dysfunction, which are known as β-cell glucotoxicity and lipotoxicity [6]. Here, INS is linked to hyperlipidemia.